1-6 of 6
Faraz Zaman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children's Oncology Group Study AALL1731

Rachel E. Rau, Sumit Gupta, John A. Kairalla, Karen R Rabin, Anne Angiolillo, Cindy Wang, Andrew J. Carroll, Susan Conway, Meenakshi Devidas, Lia Gore, Ilan R. Kirsch, Holly R. Kubaney, Amanda M Li, Jennifer L. McNeer, Olga Militano, Yvonne Moyer, Maureen M. O'Brien, Maki Okada, Shalini C. Reshmi, Mary Shago, Elizabeth R. Wagner, Naomi J. Winick, Brent L. Wood, Faraz Zaman, Gerhard Zugmaier, Sue Zupanec, Stephen P. Hunger, David T. Teachey, Elizabeth A. Raetz, Mignon L. Loh
Journal: Blood
Blood (2024) 144 (Supplement 1): 1.
https://doi.org/10.1182/blood-2024-207450
Published: 2024
Journal Articles

A Temporal and Multinational Assessment of Acute Myeloid Leukemia (AML) Cancer Incidence, Survival, and Disease Burden

Laura J. Anderson, Mariam S. Girguis, Ju-Hyeun Kim, Jitesh B. Shewale, Megan Braunlin, Winifred Werther, Juliana E. Hidalgo-Lopez, Faraz Zaman, Christopher Kim
Journal: Blood
Blood (2021) 138 (Supplement 1): 4124.
https://doi.org/10.1182/blood-2021-146251
Published: 2021
Journal Articles

Heterogeneity of Minimal/Measurable Residual Disease (MRD) Practices in Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in the United States

Juliana E. Hidalgo-Lopez, Gail J. Roboz, Brent Wood, Michael Borowitz, Elias J. Jabbour, Kelly Velasco, Ehab Elkhouly, Babatunde Adedokun, Faraz Zaman, Karim Iskander, Aaron C. Logan
Journal: Blood
Blood (2021) 138 (Supplement 1): 4478.
https://doi.org/10.1182/blood-2021-144353
Published: 2021
Journal Articles

Real World Chart Review of Blinatumomab to Treat Patients with High Disease Burden of Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Amber C. King, PharmD, BCOP, Rachel Bolanos, PhD MPH, Kelly Velasco, PharmD, Huakang Tu, PhD, Faraz Zaman, MD, Mark B. Geyer, MD, Jae H. Park, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5079.
https://doi.org/10.1182/blood-2019-122745
Published: 2019
Journal Articles

Relationship of Treatment Effects On Hemoglobin and M-Protein Levels in Relapsed or Refractory Multiple Myeloma: Final Analysis of a Retrospective Chart Review Study.

Donna E. Reece, MD, Faraz Zaman, MD, Young Trieu, MSc, Giovanni Piza Rodriguez, MD, Bruno Teixeira, HBSc, Kim Yoong, BSc, Phm, Fernando Camacho, PhD, Richard K Plante, MSc
Journal: Blood
Blood (2009) 114 (22): 4892.
https://doi.org/10.1182/blood.V114.22.4892.4892
Published: 2009
Journal Articles

A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma

Sagar Lonial, MD, Dixil Francis, Chatchada Karanes, Suzanne Trudel, Donna E. Reece, MD, Amrita Krishnan, Marc Buacharern, Renee Smith, Faraz Zaman, Engin Gul, Akari M. Dollard, Donald Harvey, Jonathan Kaufman
Journal: Blood
Blood (2008) 112 (11): 3706.
https://doi.org/10.1182/blood.V112.11.3706.3706
Published: 2008